Dr. Binod Dhakal, MD

Dr. Dhakal practices at Froedtert Hospital in Milwaukee, Wisconsin, part of Froedtert ThedaCare Health.

Dr. Dhakal's NPI, 1710218011, was assigned on January 26, 2010. Dr. Dhakal holds Wisconsin license 54325.

Dr. Dhakal's primary practice is Froedtert Hospital, at 9200 W Wisconsin Ave, Milwaukee, WI 53226 in Milwaukee County. The practice phone is (414) 805-3000.

Dr. Dhakal's primary practice is Froedtert Hospital in Milwaukee, Wisconsin, part of Froedtert ThedaCare Health. Dr. Dhakal is also affiliated with ThedaCare Regional Medical Center-Appleton. The medical group on file is Froedtert & the Medical College of Wisconsin Community Physicians. Dmand AI also links Dr. Dhakal to 3 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dhakal practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Dhakal's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Dhakal's licenses on file in 2 states: Wisconsin and Illinois.

CMS data shows 1,368 Medicare services from Dr. Dhakal across 4 procedure codes in 2024, for 208 Medicare patients. Medicare paid $86,460 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 208 Medicare patients who saw Dr. Dhakal in 2024. The largest group is 65 to 74, with 112 patients. 66% of them have high blood pressure, and 51% have high cholesterol. 8% are also on Medicaid. Their average risk score is 3.00, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dhakal's median patient age at 69, with 42% women.

In 2024, Dr. Dhakal wrote 296 Medicare Part D claims for 75 patients. 85% of them were for generic drugs. CMS names the drug for 217 of them, across 9 drugs with 11 or more claims each, at $161,602 in total drug cost. In 2023, CMS named 107 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Dhakal for performance year 2024, reported as part of a group. Dr. Dhakal accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dhakal as offering telehealth.

Dmand AI links 153 papers to Dr. Dhakal, published from 2011 to 2025. 2024 was the busiest year, with 19. The most frequent topics are Multiple Myeloma, Hematopoietic Stem Cell Transplantation and Transplantation, Autologous. Dr. Dhakal has published most often in Clin Lymphoma Myeloma Leuk. Dr. Dhakal's most frequent co-authors are Parameswaran N. Hari, MD, Anita D'Souza, MD and Saurabh Chhabra, MD.

Dmand AI links Dr. Dhakal to 8 clinical trials, 3 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Smoldering Multiple Myeloma. Cartesian Therapeutics sponsors the most, 2.

CMS Open Payments shows 460 general payments to Dr. Dhakal from 23 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 44% of the total. Janssen Pharmaceuticals, Inc paid the most, $100,704. It also lists 165 research payments totaling $327,014 from 2023 to 2025.